trending Market Intelligence /marketintelligence/en/news-insights/trending/7EP2N9CviGnpRXdYFO7LPg2 content esgSubNav
In This List

Akebia succeeds in European patent dispute a 2nd time

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Akebia succeeds in European patent dispute a 2nd time

The European Patent Office's Opposition Division revoked another of FibroGen Inc.'s patents related to hypoxia-inducible factor, or HIF, for the treatment of kidney disease.

This is the second of FibroGen's patents related to HIF that was revoked due to a challenge from Akebia Therapeutics Inc.